Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) will host a conference call on May 10, 2022, at 2 p.m. CEST to discuss its business progress in Q1 2022. The call will feature key executives, including CEO Mondher Mahjoubi and CFO Frédéric Lombard. Participants can join via webcast or telephone. Innate Pharma is dedicated to oncology innovations through therapeutic antibodies, aiming to enhance treatment outcomes for cancer patients. They have significant collaborations with top biotech firms, strengthening their pipeline against high unmet medical needs.
- Upcoming conference call on May 10, 2022, will provide insights on Q1 2022 business progress.
- Collaboration with leading biopharmaceutical companies enhances pipeline potential.
- None.
Speakers during the call will be:
-
Mondher Mahjoubi , Chief Executive Officer -
Joyson Karakunnel , Executive Vice President, Chief Medical Officer -
Yannis Morel , Executive Vice President, Product Portfolio Strategy & Business Development -
Frédéric Lombard , Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link:
https://event.on24.com/wcc/r/3759098/7B02319F4F19D3C195707D21AF02B664
Participants may also join via telephone using the dial-in details below:
All other locations: +1 929 526 1599
Access code: 051477
This information can also be found on the Investors section of the
About
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Headquartered in
Learn more about
Information about
ISIN code Ticker code LEI |
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005522/en/
For additional information:
Investors and Media
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Marie Puvieux (
Tel.: +33 981 87 46 72
innate-pharma@atcg-partners.com
Source:
FAQ
When is Innate Pharma's Q1 2022 business update conference call?
Who are the speakers during Innate Pharma's conference call?
How can I participate in Innate Pharma's conference call?
What is the focus of Innate Pharma's business updates?